THE DEAL, AT A GLANCE
2/4 reviewedDialybrid
01What it doesDialybrid develops vascular grafts for hemodialysis, using a silk-polyurethane material to create blood-access implants.Source-grounded · automated review · Explore ↗
Checked 2026-10-07 · Review due 2026-10-14
Read supporting source ↗Dialybrid S.r.l. is a clinical-stage…
02Who is involvedBacked by XGEN Venture, CDP Venture Capital (Rilancio Fund)From the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗03What happenedDialybrid raised Series A, announced 2026-10-07From the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗04Why it mattersThe funding supports clinical validation of Dialybrid’s hemodialysis graft and broader vascular material development.Source-grounded · automated review · Explore ↗
Click a part to explore its evidence. Unsupported imagery is withheld rather than guessed.Original record source ↗
Dialybrid · Financing Record
Explore source-linked visual explanations for Dialybrid. Unsupported claims are withheld while source review continues.
Record 13597 · Recorded date: 2026-10-07
Explore company records →